The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms
| Status: | Recruiting |
|---|---|
| Conditions: | Alzheimer Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 50 - 80 |
| Updated: | 4/21/2016 |
| Start Date: | January 2013 |
| End Date: | September 2016 |
| Contact: | Jan A Light, LPN |
| Email: | Light.Jan@mayo.edu |
| Phone: | (480) 301-8788 |
The investigators' goal is to determine if certain tests of memory and attention, performed
while sleepiness is induced by a single dose of lorazepam, can predict whether or not an
individual is at risk for developing Alzheimer's disease.
while sleepiness is induced by a single dose of lorazepam, can predict whether or not an
individual is at risk for developing Alzheimer's disease.
Inclusion criteria:
- MMSE score of 28-30
- Hamilton Depression Rating Scale score of less than 10
- participants in longitudinal study of aging and have a TOMM40 genotype of S/S, VL/VL,
S/VL, L/S or L/VL.
Exclusion criteria:
- Alzheimer's Disease or Mild Cognitive Impairment
- any significant medical, psychiatric, and neurological illnesses, e.g., impaired
liver or kidney function, prior stroke, traumatic brain injury, memory impairment,
cognitive impairment, parkinsonism, a lifetime history of schizophrenia, bipolar
disorder, a psychoactive substance use disorder, or current major depression.
- known allergy to benzodiazepines
- current use (within the previous four weeks) of benzodiazepines or other medications
known to interact with lorazepam, current use of sedating antihistamines, or current
use of stimulant medications
We found this trial at
1
site
Click here to add this to my saved trials
